Tag: GlobeNewswire

Company puts ATM program in place to provide flexible financing and support disciplined capital management

Company targets disciplined use of ATM to support cost-effective operations

ORLANDO, Fla., Oct. 08, 2026 (GLOBE NEWSWIRE) — Innventure, Inc. (NASDAQ: INV) (“Innventure” or the “Company”), today announced that it entered into an at-the-market equity offering agreement (the “ATM”) and has discontinued its use of the standby equity purchase agreement that it entered into with YA II PN, Ltd. in October 2023 (the “SEPA”).

The ATM provides Innventure with the flexibility to best support the Company’s operations and the ongoing development of Accelsius. The ATM provides for sales of Innventure’s common stock having an aggregate offering size of up to $60 million, however, the Company is under no obligation to sell any shares under the ATM. Any sales pursuant to the ATM are expected to occur over an extended period of time at the Company’s discretion, based on parameters established and monitored by an independent and disinterested committee of the Company’s Board of Directors (the “Board”).

“Having become eligible to use a Form S-3 shelf registration statement, we are moving away from the SEPA and established this ATM to broaden our financing options and give Innventure greater control over how and when we raise equity capital,” said Dr. Bill Grieco, Innventure’s Chief Executive Officer. “The ATM is an important tool in our capital strategy that we intend to use with discipline, taking into account market conditions, capital needs and the interests of our shareholders. Combined with the significant reduction in parent-company costs, it gives us a stronger foundation for Accelsius to achieve its milestones,” added Dr. Grieco.

“The Board has, and will continue to, carefully evaluate our overall capital structure,” said Bruce Brown, Chairman of Innventure’s Board. “The ATM provides the Board with flexibility to control the timing and extent of dilution as we focus our efforts on Accelsius as it realizes growth opportunities and creates shareholder value,” added Mr. Brown.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy securities, nor shall there be any sale of securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction.

About Innventure

Innventure (NASDAQ: INV) builds, scales and operates the companies that it has founded as they commercialize new technologies. In addition to operating the companies, Innventure is focused on preserving and maximizing the value of its operating company interests for shareholders through disciplined capital allocation, focused execution, strong governance, and strategic initiatives. Learn more at innventure.com.

Cautionary Statement Regarding Forward-Looking Statements

Certain statements in this press release are “forward-looking statements” within the meaning of the federal securities laws, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are often identified by future or conditional words such as “plan,” “believe,” “expect,” “anticipate,” “intend,” “outlook,” “estimate,” “forecast,” “project,” “continue,” “could,” “may,” “might,” “possible,” “will,” “potential,” “predict,” “should,” “would” and other similar words and expressions (or the negative versions of such words or expressions), but the absence of these words does not mean that a statement is not forward-looking.

The forward-looking statements are based on the current assumptions and expectations of future events that are inherently subject to uncertainties and changes in circumstances and their potential effects and speak only as of the date of this press release. There can be no assurance that future developments will be those that have been anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond the control of the parties) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements.

These risks and uncertainties include, but are not limited to, those factors described in Innventure’s public filings with the U.S. Securities and Exchange Commission, including, but not limited to, the following: Innventure’s and its subsidiaries’ ability to execute on their strategies, book sales and achieve future financial performance; developments and projections relating to Innventure’s and its subsidiaries’ competitors and industry; the implementation, adoption, market acceptance and success of Innventure’s and its subsidiaries’ products, business models and growth strategies; Innventure’s and its subsidiaries’ ability to generate sufficient revenue and operating cash flow; the timing and magnitude of expected cash expenditures; the availability, timing and terms of additional financing, including debt or equity financing; market conditions affecting access to capital; potential dilution resulting from future financings; Innventure’s ability to successfully implement cost reduction initiatives; risks related to recent shareholder litigation; changes in economic conditions; competitive pressures; regulatory developments; and Innventure’s ability to maintain control over its subsidiaries.

Forward‑looking statements speak only as of the date of this release, and Innventure undertakes no obligation to update them except as required by law.

Investor Relations Contact

Kyle Nagarkar, Solebury Strategic Communications
investorrelations@innventure.com

Media Contact

Gabriel Hasson, ICR Inc. / Phil Denning, ICR Inc.
Innventure@ICRinc.com

Latest award expands OSS’s role in a next-generation platform for mission-critical electronic warfare simulation

Ninth order since May 2025 brings cumulative orders to nearly $5 million, with additional opportunities expected in 2027 and 2028

ESCONDIDO, Calif., Oct. 08, 2026 (GLOBE NEWSWIRE) — One Stop Systems, Inc. (OSS or the Company) (Nasdaq: OSS), a leader in rugged Enterprise Class compute for artificial intelligence (AI), machine learning (ML) and sensor processing at the edge, today announced that a leading defense and intelligence contractor has placed a new $1 million follow-on production order in support of a next-generation GNSS testing and simulation platform. This is the ninth order from this customer since the relationship began in May 2025 and brings total orders to date to nearly an aggregate $5 million. OSS expects additional opportunities in 2027 and 2028 to support this testing and simulation platform. 

Under the latest award, OSS will provide its Gen 5 PCIe 4U short-depth server (SDS) as the compute foundation for the customer’s next-generation GNSS simulation platform. The platform is a multi-element, phase-coherent GNSS simulator designed specifically for Controlled Reception Pattern Antenna (CRPA) testing and can simultaneously simulate multiple threats, including jamming, spoofing and repeating. The follow-on award reflects continued expansion of OSS’ role in supporting the customer’s high-fidelity simulation environments for electronic warfare signal processing and complex antenna-array modeling.

“We are thrilled to build on this relationship and support the next generation of the customer’s GNSS simulation platform,” said Mike Knowles, President and CEO of OSS. “Being selected again as the program advances from Gen 2 to Gen 3 reflects what we believe is the value of our rugged, Enterprise Class compute architecture and our ability to integrate the latest GPU and CPU technologies into proven edge platforms.”

Knowles continued, “We are increasingly seeing initial platform wins develop into recurring production opportunities as customers move from development into deployment. Based on current program expectations, OSS anticipates potential additional orders on this program in 2027 and 2028. We believe it may be another example of the growing base of multi-year platform opportunities we are developing across our defense and commercial markets.”

About One Stop Systems
One Stop Systems, Inc. (Nasdaq: OSS) is a leader in AI enabled solutions for the demanding ‘edge’. OSS designs and manufactures Enterprise Class compute and storage products that enable rugged AI, sensor fusion and autonomous capabilities without compromise. These hardware and software platforms bring the latest data center performance to harsh and challenging applications, whether they are on land, sea or in the air.

OSS products include ruggedized servers, compute accelerators, flash storage arrays, and storage acceleration software. These specialized compact products are used across multiple industries and applications, including autonomous trucking and farming, as well as aircraft, drones, ships and vehicles within the defense industry.

OSS solutions address the overall AI workflow, from high-speed data acquisition to deep learning, training and large-scale inference, and have delivered many industry firsts for industrial OEM and government customers.

As one of the fastest growing segments of the multi-billion-dollar edge computing market, AI enabled solutions require-and OSS delivers-the highest level of performance in the most challenging environments without compromise.

OSS products are available directly or through global distributors. For more information, go to www.onestopsystems.com. You can also follow OSS on X, YouTube, and LinkedIn.

Forward-Looking Statements
One Stop Systems cautions you that statements in this press release that are not a description of historical facts are forward-looking statements. Words such as, but not limited to, “anticipate,” “aim,” “believe,” “contemplate,” “continue,” “could,” “design,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “seek,” “should,” “suggest,” “strategy,” “target,” “will,” “would,” and similar expressions or phrases, or the negative of those expressions or phrases, are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Statements in this press release include, but are not limited to, statements regarding the performance and capabilities of OSS’ products, including their ability to satisfy applicable customer, technical and performance requirements; the expected timing, scope and continuation of the customer’s program; potential future orders and opportunities relating to the program, including in 2027 and 2028; revenue that may be recognized from the current or any future orders; the future adoption of OSS’ technologies and applications by this or other customers; and the development and expansion of the Company’s multi-year platform opportunities, offerings and customer relationships in the defense and commercial markets. These statements are based on the Company’s current beliefs and expectations and are subject to significant risks and uncertainties. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in our business, including risks described in our prior press releases and in our filings with the Securities and Exchange Commission (SEC), including under the heading “Risk Factors” in our latest Annual Report on Form 10-K and any subsequent filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and the Company undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

Media Contacts:
Paul “PK” Averna
One Stop Systems, Inc.
Tel (703) 509-5631
Email contact

Investor Relations:
Andrew Berger
Managing Director
SM Berger & Company, Inc.
Tel (216) 464-6400
Email contact

Brings more than 25 years of experience in clinical strategy, biostatistics and regulatory submissions from Abivax, Alumis, MyoKardia and Genentech/Roche

SAN DIEGO, Oct. 08, 2026 (GLOBE NEWSWIRE) — Aardvark Therapeutics, Inc. (Aardvark or the Company) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases, today announced the appointment of David Zhang, Ph.D., MBA, to its Board of Directors, effective October 7, 2026. Dr. Zhang will serve as an independent director.

“David has spent more than 25 years designing clinical programs, analyzing pivotal trial data and supporting regulatory submissions, including the Phase 3 study design, readout and New Drug Application for CAMZYOS® (mavacamten) at MyoKardia,” said Tien Lee, M.D., Founder and Chief Executive Officer of Aardvark. “His experience and strategic perspective will be a valuable addition to our Board at an important time for Aardvark. We are pleased to welcome him.”

“Aardvark is at a pivotal moment, with important decisions ahead for ARD-101,” said Dr. Zhang. “I look forward to working with Tien and the Board to help navigate the regulatory landscape and shape the next phase of development for people living with Prader-Willi Syndrome.”

Dr. Zhang currently serves as Chief Strategy Officer of Abivax S.A., a clinical-stage biotechnology company focused on therapeutics for chronic inflammatory diseases, where he is a member of the Executive Committee and has overseen biometrics, regulatory affairs, quality assurance and health economics and outcomes research. At Abivax, he led the biometrics team through positive topline readouts of two pivotal Phase 3 trials of obefazimod in ulcerative colitis. From 2021 to 2024, he was Senior Vice President, Biometrics and Data Management at Alumis Inc., where, as a founding executive, he built the biometrics and data management functions, served as interim Chief Information Officer, and helped the company progress through its initial public offering. Previously, Dr. Zhang was Vice President, Head of Biometrics, Data Science and Digital Health at MyoKardia, Inc., where he oversaw the pivotal trial design, readout and NDA submission for CAMZYOS® (mavacamten) for treating obstructive hypertrophic cardiomyopathy prior to the company’s acquisition by Bristol Myers Squibb. Earlier in his career, he held biometrics and strategic innovation leadership roles at Roche Sequencing Solutions and Genentech/Roche over a 15 year period, and statistician roles at Eli Lilly and Company and Abbott Laboratories. Dr. Zhang serves on the board of directors of the Bay Area Biotech-Pharma Statistics Workshop and is a past president of the organization. He holds a Ph.D. in biostatistics from the UCLA Fielding School of Public Health and an executive MBA in finance from the Kelley School of Business at Indiana University, and completed postdoctoral research in statistical genetics at Columbia University.

About Aardvark Therapeutics, Inc.

Aardvark is a clinical-stage biopharmaceutical company developing novel, small-molecule therapeutics designed to suppress hunger for the treatment of Prader-Willi Syndrome (PWS) and metabolic diseases. Hunger, which is the discomfort from not having eaten recently, is a distinct neural signaling pathway separate from appetite, the reward-seeking desire for food. Our programs explore therapeutic applications in hunger-associated indications and potential complementary uses with anti-appetite therapies. For more information, visit www.aardvarktherapeutics.com.

Forward-Looking Statements

Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements.” These statements include, but are not limited to, statements concerning: Aardvark’s business strategy, product candidates, the regulatory path forward for ARD-101, including the design of any future Phase 3 study, the anticipated contributions of Dr. Zhang to the Board of Directors and the Company’s programs, as well as plans and objectives of management for future operations. The words, without limitation, “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these or similar identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: uncertainties related to the FDA clinical hold on ARD-101 and Aardvark’s ongoing engagement with the FDA; the risk of unfavorable clinical trial results; the risk that results from earlier clinical trials and preclinical studies may not necessarily be predictive of future results; the risk that Aardvark may use its capital resources sooner than expected; the possibility that the past track records of Aardvark and its personnel may not be repeated or indicative of future success; and other risks and uncertainties, including the factors described under the “Risk Factors” section of Aardvark’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2026 filed with the Securities and Exchange Commission on August 11, 2026. When evaluating Aardvark’s business and prospects, careful consideration should be given to these risks and uncertainties. Any forward-looking statements contained in this press release are based on the current expectations of Aardvark’s management team and speak only as of the date hereof, and Aardvark specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise, unless required by law.

Investor and Media Contact
Argot Partners
(212) 600-1902
Aardvark@Argotpartners.com

Launch expands ROC’s commercial growth strategy, delivers NIST-ranked facial age estimation via enterprise API

DENVER, CO, Oct. 08, 2026 (GLOBE NEWSWIRE) — Rank One Computing Corporation d/b/a ROC, (Nasdaq: ROC) (“ROC” or the “Company”), a U.S. leader in Vision AI, building unified biometric, video analytics, and digital evidence solutions, today announces the launch of its Age Estimation API, a new self-service offering that gives U.S. businesses direct production access to ROC’s facial age estimation technology via a Web API. The launch marks ROC’s first Software-as-a-Service (SaaS) offering and advances the Company’s broader strategy to expand its revenue base beyond enterprise access by making its Vision AI capabilities available through SaaS and APIs.

“ROC has built age estimation technology that ranks among the best globally, and now we’re making it more accessible to the developer community,” said ROC CEO B. Scott Swann. “This foundational SaaS offering is a material advancement in our product set and the start of a broader strategy that creates a compelling new revenue stream in our commercial business. Over time, we anticipate launching additional SaaS and API offerings to developers and integration partners, including face analytics and biometrics.”

ROC’s SaaS offering is designed for developers and product teams building age-assurance workflows. The API enables customers to submit a supported facial image and receive a structured age estimate rooted in ROC’s NIST-ranked age estimation technology that can be incorporated into their own thresholds, access rules, safeguards, and escalation processes. With increasing market demand for security and safety harnesses across commercial and enterprise business, the API supports age-assurance applications spanning social and community platforms, age-gated content and services, gaming, digital onboarding, and age-restricted commerce. Developers can build and test against the same API used in production, with submitted facial images processed in real time and immediately discarded. Facial images and biometric data are not retained or stored, and requests are processed without human review.

ROC’s age estimation technology has been independently evaluated through the National Institute of Standards and Technology’s (NIST) Face Analysis Technology Evaluation (FATE) Age Estimation & Verification (AEV) benchmark. The Company ranked first globally in Mean Absolute Error (MAE) across NIST’s Visa, Application, and Mugshot datasets for adults ages 18 to 30, and first globally in MAE on NIST’s Child Online Safety dataset, which evaluates age estimation for individuals ages 13 to 16. Lower MAE indicates a closer average age estimate.

Learn more about ROC’s Age Estimation API for developers and integrators.

About ROC
ROC is a leading U.S. developer and manufacturer of Vision AI, delivering sovereign biometrics, video analytics, and digital evidence through a unified platform. This enables agency and integrator partners to unlock faster, more accurate, and cost-efficient capabilities. At its core, ROC transforms raw pixels into real-time operational awareness for defense, public safety, and digital commerce. The Company is headquartered in Denver, Colo., with additional hubs in Grand Rapids, Mich., and Morgantown, W.V. For more information, please visit the Company’s website: www.roc.ai.

Forward-Looking Statements
This Press Release may contain forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “confident,” and similar statements. Actual results may differ materially and adversely from those expressed in any forward-looking statements. ROC may also make written or oral forward-looking statements in its periodic reports to the SEC, in its annual report to shareholders, in press releases and other written materials, and in oral statements made by its officers, directors, or employees to third parties. Statements that are not historical facts, including statements about the parties’ beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: (i) ROC’s goals and strategies and (ii) ROC’s future business development, financial condition, and results of operations. Further information regarding these and other risks is included in ROC’s filings with the SEC. All information provided in this press release is provided, and the forward-looking statements included herein are made, solely as of the date of this press release, and neither party undertakes any obligation to revise or update any forward-looking statement, except as required under applicable law.

Media inquiries:
Matt Aitken, VP of Marketing
media@roc.ai

Investor inquiries:
CORE IR
ir@roc.ai

The leading waxing franchise continues its category dominance, earning the top spot for the fifth consecutive year

PLANO, Texas, Oct. 08, 2026 (GLOBE NEWSWIRE) — European Wax Center, Inc., the leading franchisor and operator of out-of-home waxing services, has been recognized in Entrepreneur’s Best of the Best 2026 list, earning the No. 1 franchise ranking in the Waxing category.

Entrepreneur’s Best of the Best list celebrates industry-leading franchises across categories distinguished among Entrepreneur’s annual Franchise 500^®. After evaluating over 1,000 franchise brands across more than 150 data points, including costs and fees, size and growth, franchisee support, brand strength, and financial strength and stability, Entrepreneur ranked EWC as the No. 1 franchise in waxing for the fifth year in a row.

“Being named No. 1 in waxing on Entrepreneur’s Best of the Best list for the fifth consecutive year is an honor,” said Chris Morris, Chief Executive Officer of European Wax Center. “This achievement reflects the dedication of our franchisees and showcases our shared commitment to delivering an exceptional experience for every guest.”

This ranking reflects over two decades of building a category-leading brand grounded in consistent guest experience and a strong franchise network. EWC offers a full suite of waxing services in over 1,000 centers nationwide and an award-winning product line created for pre- and post-waxing.

The recognition follows a year in which EWC underwent a brand transformation and introduced Smooth, Done Right™. A new brand platform that puts the company’s decades of waxing expertise front and center. The transformation extends across the EWC experience, from a refreshed visual identity and new brand campaign to redesigned centers rolling out across the country.

To learn more about opening a European Wax Center franchise, please visit https://waxcenter.com/pages/ewc-franchise-page.

About European Wax Center, Inc.

Founded in 2004, European Wax Center, Inc. is the leading franchisor and operator of out-of-home waxing services in the United States. The Company’s highly trained wax specialists receive extensive training and draw on insights gained from more than 100 million waxing services to combine specialized expertise, proprietary techniques, and a guest-first approach to deliver consistent, professional experiences across the brand’s 1,000+ locations nationwide. The Company continues to revolutionize the waxing industry with its innovative Comfort Wax®, formulated with high-quality ingredients to make waxing more efficient and less painful, along with proprietary products to help enhance and extend waxing results. For more information, please visit: https://waxcenter.com.

CONTACT: Sophia Tortorella
Sophia.Tortorella@zenogroup.com

BRIDGEWATER, N.J., Oct. 08, 2026 (GLOBE NEWSWIRE) — Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) (“Amneal” or the “Company”), today announced it will report third quarter 2026 financial results on Tuesday, November 3, 2026, before market open. The Company will host an audio webcast at 8:30 a.m. ET.

The financial results and live webcast will be available through the Investor Relations section of the Company’s website at investors.amneal.com. Individuals may register for the webcast by clicking here. To access the call by phone, dial 1 (833) 461-5787 (U.S.) or view a list of toll-free international numbers here. The access code is 304152835. A replay of the webcast will be available shortly after the call.

About Amneal
Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX), headquartered in Bridgewater, New Jersey, is a diversified, global biopharmaceutical leader focused on expanding access to affordable and innovative medicines. Amneal was founded in 2002 by brothers and co-CEOs Chirag and Chintu Patel, and built on the belief that innovation only matters if it’s accessible. Today, Amneal has a diverse and growing portfolio of approximately 300 complex generic, specialty and biosimilar medicines, delivering more than 160 million prescriptions annually, primarily in the United States. Our Affordable Medicines segment spans retail generics, injectables, and biosimilars. Our Specialty segment provides branded treatments in neurology, including Parkinson’s disease and migraine, and endocrinology. Our AvKARE segment distributes pharmaceuticals and medical products to U.S. federal, retail, and institutional customers. For more information, visit  and follow us on LinkedIn.

Investor Contact
Anthony DiMeo
VP, Investor Relations
anthony.dimeo@amneal.com 

TORONTO, Oct. 08, 2026 (GLOBE NEWSWIRE) — Quantum BioPharma Ltd. (NASDAQ: QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, today announced that the United States District Court for the Southern District of New York has agreed to consolidate both the Company’s direct action and a class action led by an individual investor alleging market manipulation. In addition, the court appointed experienced law firm Grant & Eisenhofer P.A. (“Grant & Eisenhofer”) as lead counsel in the class action. According to Grant & Eisenhofer, the firm has recovered over USD $30 Billion dollars for its clients to date in some of the most complex, often precedent-setting cases, in fights against the world’s largest and richest opponents.

The Quantum Biopharma lawsuit alleged that between January 1, 2020, and August 15, 2024, the Defendants and/or their customers used “spoofing” techniques to manipulate the share price of Quantum BioPharma shares. The class action lawsuit filed December 11, 2025, alleges that between January 6, 2021, and October 15, 2025, shareholders who sold securities of Quantum Biopharma Ltd., formerly known as FSD Pharma Inc., were significantly and materially harmed.

A link to the Court’s ruling can be found here: Opinion and Order 25-cv-10565 (ER)

For more information visit: www.quantumbiopharma.com under the page Quantum vs Banks.

About Quantum BioPharma Ltd.

Quantum is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc. (“Lucid”), Quantum is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. Quantum invented UNBUZZD™ and spun out its OTC version to Unbuzzd Wellness Inc. (“Unbuzzd”) (formerly, Celly Nutrition Corp.), led by industry veterans. Quantum retains ownership of 19.48% (as of June 30, 2026) of Unbuzzd. The agreement with Unbuzzd also includes royalty payments of 7% of sales from unbuzzd™ until payments to Quantum total $250 million. Once $250 million is reached, the royalty drops to 3% in perpetuity. Quantum retains 100% of the rights to develop similar products or alternative formulations specifically for pharmaceutical and medical uses.

For more information visit www.quantumbiopharma.com.

Forward-Looking Information

This news release contains “forward-looking statements” within the meaning of applicable securities laws, including the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements other than statements of historical fact and may include statements regarding the Company’s litigation against the defendants, the effect of the Court’s decision to consolidate the related actions, the conduct and timing of the consolidated litigation, the Company’s ability to pursue its claims, the potential recovery of damages or other relief, and the Company’s expectations regarding the ultimate outcome of the litigation. Forward-looking statements are often identified by words such as “may,” “will,” “should,” “expect,” “anticipate,” “believe,” “intend,” “estimate,” “potential,” “continue,” “could” and similar expressions, although not all forward-looking statements contain these identifying words.

Forward-looking statements are based on management’s current expectations, assumptions and beliefs and are subject to significant risks, uncertainties and other factors that could cause actual results or events to differ materially from those expressed or implied by such statements. These risks and uncertainties include, among others, the inherent uncertainty, cost and duration of litigation; the possibility of appeals, procedural rulings, delays, settlement discussions or other developments; the Company’s ability to prove its allegations and establish liability, causation and damages; the defendants’ defenses and counterarguments; the amount, if any, of damages or other relief that may ultimately be awarded or recovered; the collectability of any judgment or settlement; and other risks described in the Company’s filings with the U.S. Securities and Exchange Commission. The Court’s consolidation of the related actions and appointment of lead counsel are procedural developments and do not constitute a determination on the merits of the Company’s claims or any finding of liability or damages. There can be no assurance that the litigation will result in a favorable judgment, settlement, recovery of the amount claimed, or any recovery at all.

Readers are cautioned not to place undue reliance on forward-looking statements. The forward-looking statements in this news release speak only as of the date hereof and are expressly qualified in their entirety by this cautionary statement. Except as required by applicable law, the Company undertakes no obligation to update or revise any forward-looking statement as a result of new information, future events or otherwise.

Contacts:

Investor Relations
Robert Guzman, Investor Relations
Email: Rob@QuantumBioPharma.com
Telephone: (833) 304-0323
General Inquiries: info@QuantumBioPharma.com

TEL AVIV, Israel, Oct. 08, 2026 (GLOBE NEWSWIRE) — Entera Bio Ltd. (NASDAQ: ENTX) (“Entera” or the “Company”), a leader in the development of oral peptides, today announced that an additional presentation highlighting the clinical study design for its planned Phase 3 registrational trial of EB613 (oral PTH(1-34) tablet) will be presented at the American Society for Bone and Mineral Research (ASBMR) 2026 Annual Meeting, taking place October 9-12, 2026, at the John B. Hynes Veterans Memorial Convention Center in Boston, Massachusetts.

The additional presentation, titled “EB613 [Oral PTH(1-34)]: The First Oral Anabolic Tablet for the Treatment of Osteoporosis: Phase 3 Study Design,” has been accepted as a late-breaking poster presentation (Presentation Number: Sun-522) during Late Breaking Poster Session II on Sunday, October 11, 2026. Led by Dr. Felicia Cosman, Professor of Medicine at Columbia University and an internationally recognized osteoporosis authority, the presentation will outline the study design and clinical methodology for Entera’s planned single, randomized, double-blind, placebo-controlled Phase 3 registrational study evaluating EB613 in postmenopausal women with osteoporosis.

This presentation is in addition to the Company’s Phase 2 clinical data for EB613 which was selected for a Plenary Poster presentation at the meeting, evaluating treatment effects in postmenopausal women with osteopetrosis at high risk of fracture.

Presentation Details:

Abstract Title: EB613 [Oral PTH(1-34)]: The First Oral Anabolic Tablet for the Treatment of Osteoporosis: Phase 3 Study Design

Session Title: Late Breaking Poster Session II
Presentation Number: Sun-522
Session Date/Time: Sunday, October 11, 2026, 2:00-3:30 p.m. ET

Abstract Title: EB613, Oral PTH(1-34) Tablet, Shows Markedly Enhanced Anabolic Effects in Postmenopausal Women with Osteoporosis at High Risk of Fracture: Insights from Phase 2 Trial

Session Title: Welcome Reception and Plenary Poster Session (Plenary Poster Presentation)
Presentation Number: Fri-026
Session Date/Time: Friday, October 9, 2026, 5:30-7:00 p.m. ET

Session Title: Poster Session II
Presentation Number: Sun-026
Session Date/Time: Sunday, October 11, 2026, 2:00-3:30 p.m. ET

About EB613
Substantial evidence supports the efficacy of anabolic therapies over anti-resorptive agents for lowering fracture risk in osteoporosis patients at high risk. However, all available anabolic therapies are administered by subcutaneous (SC) injection and used in a minority of eligible patients. Entera’s EB613 program (oral PTH(1-34), teriparatide) is being developed as the first oral, once-daily anabolic tablet treatment for osteoporosis. Entera completed a Phase 2, 6-month, 161-patient, placebo-controlled study that met all biomarker and BMD endpoints without significant safety concerns in women with postmenopausal osteoporosis or low BMD (JBMR 2024). EB613 produced rapid dose-proportional increases in biochemical markers of bone formation, reductions in markers of bone resorption, and increases in lumbar spine, total hip, and femoral neck BMD. The effects of EB613 on trabecular and cortical bone using 3D-DXA showed increases with EB613 compared to placebo on a variety of indices, including integral volumetric BMD and trabecular volumetric BMD, cortical thickness, and cortical surface BMD. Mechanistically, the findings suggest that bone strengthening and fracture resistance may occur rapidly with EB613. Furthermore, the data are consistent with that of published subcutaneous teriparatide at the 6-month time point.

About Entera
Entera is a clinical stage company focused on developing oral peptide and protein replacement therapies for significant unmet medical needs where an oral tablet form holds the potential to transform the standard of care. The Company leverages a disruptive and proprietary technology platform (N-Tab®) and its pipeline of first-in-class oral peptide programs. The Company’s most advanced product candidate, EB613 (oral PTH(1-34)), is being developed as the first oral, osteoanabolic (bone building) once-daily tablet for osteoporosis. A placebo-controlled, dose-ranging Phase 2 study of EB613 tablets (n = 161) met primary (PD/bone turnover biomarker) and secondary endpoints (BMD). Entera is also developing the first oral Long Acting PTH(1-34) tablet as a replacement therapy for patients with hypoparathyroidism (EB612), the first oral oxyntomodulin, a dual targeted GLP1/glucagon peptide tablet for the treatment of obesity and metabolic syndromes; and the first oral GLP-2 tablet as an injection-free alternative for patients suffering from rare malabsorption conditions such as short bowel syndrome in collaboration with OPKO Health, Inc. For more information on Entera, visit www.enterabio.com or follow us on LinkedIn, Twitter, and Facebook.

Cautionary Statement Regarding Forward Looking Statements
Various statements in this press release are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements (other than statements of historical facts) in this press release regarding our prospects, plans, financial position, business strategy, clinical development activities, collaboration arrangements and expected financial and operational results are forward-looking statements. Words such as, but not limited to, “anticipate,” “believe,” “can,” “could,” “expect,” “estimate,” “design,” “goal,” “intend,” “may,” “might,” “objective,” “plan,” “predict,” “project,” “target,” “likely,” “should,” “will,” and “would,” or the negative of these terms and similar expressions or words, identify forward-looking statements. Forward-looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions and uncertainties. Forward-looking statements should not be read as a guarantee of future performance or results and may not be accurate indications of when such performance or results will be achieved. Important factors that could cause actual results to differ materially from those reflected in Entera’s forward-looking statements include, among others: changes in the interpretation of clinical data; results of our clinical trials; the FDA’s interpretation and review of our results from and analysis of our clinical trials; unexpected changes in our ongoing and planned preclinical development and clinical trials, the timing of and our ability to make regulatory filings and obtain and maintain regulatory approvals for our product candidates; the potential disruption and delay of manufacturing supply chains; loss of available workforce resources, either by Entera or its collaboration and laboratory partners; impacts to research and development or clinical activities that Entera may be contractually obligated to provide; overall regulatory timelines; the size and growth of the potential markets for our product candidates; the scope, progress and costs of developing Entera’s product candidates; Entera’s reliance on third parties to conduct its clinical trials; Entera’s ability to establish and maintain development and commercialization collaborations; Entera’s operation as a development stage company with limited operating history; Entera’s competitive position with respect to other products on the market or in development for the treatment of osteoporosis, hypoparathyroidism, short bowel syndrome, obesity, metabolic conditions and other disease categories it pursues; Entera’s ability to continue as a going concern absent access to sources of liquidity; Entera’s ability to obtain and maintain regulatory approval for any of its product candidates; Entera’s ability to comply with Nasdaq’s minimum listing standards and other matters related to compliance with the requirements of being a public company in the United States; Entera’s intellectual property position and its ability to protect its intellectual property; and other factors that are described in the “Cautionary Statement Regarding Forward-Looking Statements,” “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of Entera’s most recent Annual Report on Form 10-K filed with the SEC, as well as Entera’s subsequently filed Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. There can be no assurance that the actual results or developments anticipated by Entera will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, Entera. Therefore, no assurance can be given that the outcomes stated or implied in such forward-looking statements and estimates will be achieved. Entera cautions investors not to rely on the forward-looking statements Entera makes in this press release. The information in this press release is provided only as of the date of this press release, and Entera undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except to the extent required by law.

Company Contact:
IR@enterabio.com

• Three scientific presentations will highlight new analyses of VOQUEZNA^® (vonoprazan) in GERD, including real-world patient characteristics, efficacy across BMI subgroups, and cost-effectiveness in Erosive Esophagitis

FLORHAM PARK, N.J., Oct. 08, 2026 (GLOBE NEWSWIRE) — Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today announced its participation in the American College of Gastroenterology (ACG) 2026 Annual Scientific Meeting, being held October 9-14 in Nashville, Tennessee.

Phathom will present three scientific posters featuring new data and analyses for VOQUEZNA^® (vonoprazan) in Gastroesophageal Reflux Disease (GERD), including a post hoc analysis of VOQUEZNA efficacy in patients with Non-Erosive GERD across Body Mass Index (BMI) subgroups, a retrospective analysis of real-world patient characteristics, and a model examining the cost-effectiveness of VOQUEZNA compared with proton pump inhibitors (PPIs) in Erosive Esophagitis, or Erosive GERD. The Company will also host a Product Theater to highlight the clinical efficacy and safety profile of VOQUEZNA.

“ACG provides an important opportunity to continue advancing the scientific dialogue around GERD and share new insights with the GI community,” said Steve Basta, President and Chief Executive Officer of Phathom. “These analyses add to the growing body of data on VOQUEZNA and provide new perspectives relevant to its use in GERD. We look forward to discussing these findings with GI healthcare providers and hearing firsthand perspectives from clinicians and patients throughout the meeting.”

Phathom’s Presentations at ACG 2026:

Sunday, October 11, 2026

• Vonoprazan Efficacy Across BMI Subgroups in Non-Erosive Reflux Disease
  • Poster: P0624
  • Time: 3:30 PM – 7:00 PM CDT
  • Presenter: Catiele Antunes, MD, Assistant Professor of Medicine and Director of the Refractory GERD Clinic at Yale School of Medicine

Monday, October 12, 2026

• Characteristics of US Patients With Gastroesophageal Reflux Disease (GERD) Taking Vonoprazan or a Prescription Proton Pump Inhibitor (PPI)
  • Poster: P2921
  • Time: 10:30 AM – 4:15 PM CDT
  • Presenter: Nicholas J. Shaheen, MD, MPH, Chief of the Division of Gastroenterology and Hepatology and Bozymski-Heizer Distinguished Professor of Medicine at the UNC School of Medicine

• VOQUEZNA^® (vonoprazan) Product Theater: Beyond the Data: From Clinical Cases to Patient Perspectives
  • Location: Booth #117 – ACG Product Theater
  • Time: 3:45 PM CDT
  • Presenters: John E. Pandolfino, MD, MSCI, Chief of Gastroenterology and Hepatology and Hans Popper Professor of Medicine at Northwestern University Feinberg School of Medicine; and a Patient Speaker

Tuesday, October 13, 2026

• Cost-Effectiveness of Vonoprazan Versus Proton Pump Inhibitors in Adults With Erosive Esophagitis in the United States: A Markov Model of Lifetime Outcomes
  • Poster: P5160
  • Time: 10:30 AM – 4:00 PM CDT
  • Presenter: Nicholas J. Shaheen, MD, MPH, Chief of the Division of Gastroenterology and Hepatology and Bozymski-Heizer Distinguished Professor of Medicine at the UNC School of Medicine

Attendees can also visit Phathom’s Medical Affairs and Commercial teams on the exhibit floor at Booth 323.

About VOQUEZNA
INDICATIONS AND USAGE
VOQUEZNA^® (vonoprazan) is a potassium-competitive acid blocker (PCAB) indicated in adults:

• for the healing of all grades of Erosive Esophagitis (Erosive Gastroesophageal Reflux Disease or Erosive GERD) and relief of heartburn associated with Erosive GERD.
• to maintain healing of all grades of Erosive GERD and relief of heartburn associated with Erosive GERD.
• for the relief of heartburn associated with Non-Erosive GERD.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

VOQUEZNA is contraindicated in patients with a known hypersensitivity to vonoprazan or any component of VOQUEZNA, or in patients receiving rilpivirine-containing products.

WARNINGS AND PRECAUTIONS

Presence of Gastric Malignancy: In adults, symptomatic response to therapy with VOQUEZNA does not preclude the presence of gastric malignancy. Consider additional follow-up and diagnostic testing in patients who have a suboptimal response or an early symptomatic relapse after completing treatment with VOQUEZNA. In older patients, also consider endoscopy.

Acute Tubulointerstitial Nephritis: Acute tubulointerstitial nephritis (TIN) has been reported with VOQUEZNA. If suspected, discontinue VOQUEZNA and evaluate patients with suspected acute TIN.

Clostridioides difficile-Associated Diarrhea: Published observational studies suggest that proton pump inhibitors (PPIs) may be associated with an increased risk of Clostridioides difficile-associated diarrhea (CDAD), especially in hospitalized patients. VOQUEZNA may also increase the risk of CDAD. Consider CDAD in patients with diarrhea that does not improve. Use the shortest duration of VOQUEZNA appropriate to the condition being treated.

Bone Fracture: Several published observational studies suggest that PPI therapy may be associated with an increased risk for osteoporosis-related fractures of the hip, wrist, or spine, especially in patients receiving high dose (multiple daily doses) and long-term therapy (a year or longer). Bone fracture, including osteoporosis-related fracture, has also been reported with vonoprazan. Use the shortest duration of VOQUEZNA appropriate to the condition being treated. Patients at risk for osteoporosis-related fractures should be managed according to the established treatment guidelines.

Severe Cutaneous Adverse Reactions (SCAR): Severe cutaneous adverse reactions, including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) have been reported with VOQUEZNA. Discontinue VOQUEZNA at the first signs or symptoms of SCAR or other signs of hypersensitivity and consider further evaluation.

Vitamin B12 (Cobalamin) Deficiency: Long-term use of acid-suppressing drugs can lead to malabsorption of Vitamin B12 caused by hypo- or achlorhydria. Vitamin B12 deficiency has been reported postmarketing with vonoprazan. If clinical symptoms consistent with vitamin B12 deficiency are observed in patients treated with VOQUEZNA, consider further workup.

Hypomagnesemia and Mineral Metabolism: Hypomagnesemia has been reported postmarketing with vonoprazan. Hypomagnesemia may lead to hypocalcemia and/or hypokalemia and may exacerbate underlying hypocalcemia in at-risk patients.

Consider monitoring magnesium levels prior to initiation of VOQUEZNA and periodically in patients expected to be on prolonged treatment, in patients taking drugs that may have increased toxicity in the presence of hypomagnesemia or drugs that may cause hypomagnesemia. Treatment of hypomagnesemia may require magnesium replacement and discontinuation of VOQUEZNA.

Consider monitoring magnesium and calcium levels prior to initiation of VOQUEZNA and periodically while on treatment in patients with a preexisting risk of hypocalcemia. Supplement with magnesium and/or calcium, as necessary. If hypocalcemia is refractory to treatment, consider discontinuing VOQUEZNA.

Interactions with Diagnostic Investigations for Neuroendocrine Tumors: Serum chromogranin A (CgA) levels increase secondary to drug-induced decreases in gastric acidity. The increased CgA level may cause false positive results in diagnostic investigations for neuroendocrine tumors. Temporarily discontinue VOQUEZNA treatment at least 4 weeks before assessing CgA levels and consider repeating the test if initial CgA levels are high.

Fundic Gland Polyps: Use of VOQUEZNA is associated with a risk of fundic gland polyps that increases with long-term use, especially beyond one year. Fundic gland polyps have been reported with vonoprazan in clinical trials and during postmarketing use with PPIs. Most patients who developed fundic gland polyps were asymptomatic and fundic gland polyps were identified incidentally on endoscopy. Use the shortest duration of VOQUEZNA appropriate to the condition being treated.

ADVERSE REACTIONS

Healing of Erosive GERD: The most common adverse reactions (≥2% of patients in the VOQUEZNA arm) include gastritis (3%), diarrhea (2%), abdominal distention (2%), abdominal pain (2%), and nausea (2%).

Maintenance of Healed Erosive GERD: The most common adverse reactions (≥3% of patients in the VOQUEZNA arm) include gastritis (6%), abdominal pain (4%), dyspepsia (4%), hypertension (3%), and urinary tract infection (3%).

Relief of Heartburn Associated with Non-Erosive GERD: The most common adverse reactions (≥2% of patients in the VOQUEZNA arm) include abdominal pain (2%), constipation (2%), diarrhea (2%), nausea (2%), and urinary tract infection (2%).

DRUG INTERACTIONS

VOQUEZNA has the potential for clinically important drug interactions, including interactions with drugs dependent on gastric pH for absorption, drugs that are substrates for certain CYP enzymes, and some diagnostic tests. Avoid concomitant use of VOQUEZNA with atazanavir or nelfinavir. See full Prescribing Information for more details about important drug interactions. Consult the labeling of concomitantly used drugs to obtain further information about interactions with vonoprazan.

USE IN SPECIFIC POPULATIONS

Pregnancy: There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to VOQUEZNA during pregnancy. Healthcare providers are encouraged to register patients by calling 1-866-609-1612 or visiting https://voqueznapregnancyregistry.com/.

Lactation: There are no data on the effects of vonoprazan on the breastfed child or the effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for VOQUEZNA and any potential adverse effects on the breastfed child from VOQUEZNA or from the underlying maternal condition.

Renal Impairment: For the healing of Erosive GERD, dosage reduction is recommended in patients with severe renal impairment (eGFR < 30 mL/min).

Hepatic Impairment: For the healing of Erosive GERD, dosage reduction is recommended in patients with moderate to severe hepatic impairment (Child-Pugh Class B and C).

You are encouraged to report suspected adverse reactions by contacting Phathom Pharmaceuticals at 1-888-775-PHAT (7428) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please click here for full Prescribing Information for VOQUEZNA.

About Phathom Pharmaceuticals, Inc. 
Phathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases. Phathom has in-licensed the exclusive rights to vonoprazan, a first-in-class potassium-competitive acid blocker (PCAB), for the U.S., Europe and Canada. Phathom currently markets vonoprazan in the United States as VOQUEZNA^® (vonoprazan) tablets for the relief of heartburn associated with Non-Erosive GERD in adults, the healing and maintenance of healing of Erosive GERD in adults and relief of associated heartburn, and as part of the VOQUEZNA^® TRIPLE PAK^® (vonoprazan tablets, amoxicillin capsules, clarithromycin tablets) and VOQUEZNA^® DUAL PAK^® (vonoprazan tablets, amoxicillin capsules) for the treatment of H. pylori infection in adults. For more information about Phathom, visit the company’s website at www.phathompharma.com and follow on LinkedIn and X.

Forward-Looking Statement
This press release contains forward-looking statements, including statements regarding Phathom’s planned participation in and presentations at the ACG 2026 Annual Scientific Meeting. These forward-looking statements are subject to certain risks and uncertainties that could cause actual results or events to differ materially from those expressed or implied by such statements, including risks and uncertainties associated with the Company’s business described under the heading “Risk Factors” in Phathom’s Annual Report on Form 10-K for the year ended December 31, 2025, as updated by Phathom’s subsequent filings with the U.S. Securities and Exchange Commission. Any forward-looking statements in this press release speak only as of the date of this press release, and Phathom undertakes no obligation to update such statements, except as required by law.

MEDIA CONTACT
Nick Benedetto
1-877-742-8466
media@phathompharma.com

INVESTOR CONTACT
Eric Sciorilli
1-877-742-8466
ir@phathompharma.com

© 2026 Phathom Pharmaceuticals. All rights reserved.
VOQUEZNA, Phathom Pharmaceuticals, and their respective logos are registered trademarks of Phathom Pharmaceuticals, Inc.

09/26 US-VPZ-26-0310

By lowering the engineering effort between an idea and the hardware, the new feature enables faster experimentation while keeping scientists in control

PARIS, Oct. 08, 2026 (GLOBE NEWSWIRE) — Pasqal (Nasdaq: PSQL), a global leader in neutral-atom quantum computing, today announced the availability of an AI-assisted workflow on Pasqal Cloud. Available as a plugin for leading agentic coding environments, the new feature can take a well-defined scientific idea to a running experiment on a quantum processing unit (QPU), significantly reducing the engineering effort that has long stood between an idea for a quantum use case and its execution on hardware.

As quantum computers become easier to access through the cloud, the challenge is shifting from hardware availability to how researchers design, run and interpret quantum experiments. Translating a protocol into a hardware-ready job still requires specialized engineering expertise and significant time. As a result, many promising ideas go untested, even when suitable hardware exists.

The AI-assisted workflow orchestrates the full pipeline. Starting from an experiment described in a paper or conceived as an original idea, it extracts or formalizes the protocol, translates it into a hardware-ready quantum job, validates it in emulation, submits it through the cloud and processes the results into scientific observables.

“The bottleneck in quantum computing is shifting,” said Wasiq Bokhari, CEO of Pasqal. “The engineering work that once demanded a researcher’s attention can increasingly be automated, allowing researchers to focus more fully on the science. Our QPUs are deployed and accessible in the cloud today. With this AI-assisted workflow lowering the barrier to using them, we are making quantum computing power available to a much broader community.”

Rather than replacing scientists, the workflow is designed to keep scientific judgment at the center. It coordinates the engineering and removes friction, while ideation, validation and decisions about what to measure and whether a result genuinely supports a physical claim, remain with the users.

The AI-assisted workflow can be installed as a plugin in leading agentic coding environments, including Claude Code, Cursor, Codex and others. Experiments can then be run on three Pasqal Cloud QPUs available to external users: Ruby, operated by GENCI at CEA, located in France, FC1, located in Sherbrooke (Québec, Canada) and SA1, located in the Kingdom of Saudi Arabia.

To learn more about the AI-assisted workflow, read our blog post, “Turning Ideas into QPU Experiments: How Agentic Workflows Make Quantum Computing More Accessible,” for a full technical deep dive, or visit the documentation.

Contacts

Investors
investors@pasqal.com 

Media
pr@pasqal.com

About Pasqal
Pasqal (Nasdaq: PSQL) helps organizations tackle problems that are difficult or impossible to solve with conventional computing methods alone. Founded in 2019 on Nobel Prize–winning research, Pasqal builds and operates neutral-atom quantum computers, delivered with a full software stack, for industry, science, and governments. Pasqal’s production-ready systems are available both on-premises and through the cloud, enabling organizations to harness quantum computing without requiring in-house quantum expertise. A single hardware platform supports analog workloads today and is designed to evolve toward fault-tolerant quantum computing in the future. 

Headquartered in France with operations globally, Pasqal’s quantum computing systems are used by customers across energy, financial services and advanced materials to address complex challenges. Pasqal’s customers include Saudi Aramco, Crédit Agricole CIB, LG Electronics and supported by partnerships with NVIDIA and IBM (Pasqal is part of the IBM Quantum Network). 

Forward-Looking Statements
Certain statements herein may be considered “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements generally are accompanied by words such as “believe,” “may,” “might”, “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “could,” “plan,” “predict,” “project”, “forecast,” “potential,” “seem,” “seek,” “target,” “possible,” “future,” “outlook” or similar terminology or expressions that predict or indicate future events or trends. These forward-looking statements include, but are not limited to, statements regarding future events, including Pasqal’s ability to accelerate global deployment of its quantum computing platform.

These statements are based on current expectations and are not predictions of actual performance. They are provided for illustrative purposes only and must not be relied on as a guarantee, prediction or definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and are beyond the control of Pasqal. These statements are subject to known and unknown risks and uncertainties and assumptions regarding Pasqal’s business, and actual results may differ materially. These risks and uncertainties include, but are not limited to: general economic, political, social and business conditions; uncertainty or changes with respect to laws and regulations; risks related to Pasqal’s indebtedness; the risk from Pasqal pursuing an emerging technology, facing significant technical challenges and the potential that it may not achieve commercialization or market acceptance; Pasqal’s reliance on strategic partners and other third parties; Pasqal’s ability to maintain, protect and defend its intellectual property rights; and other risks that will be detailed from time to time in filings with the U.S. Securities and Exchange Commission (the “SEC”). The foregoing list of risk factors is not exhaustive. There may be additional risks that Pasqal does not know or currently believes are immaterial that could also cause actual results to differ from those contained in forward-looking statements. In addition, forward-looking statements provide Pasqal’s expectations, plans and forecasts of future events and views as of the date of this communication. While Pasqal may elect to update these forward-looking statements in the future, Pasqal specifically disclaims any obligation to do so.